Antineoplastic agents. 565. Synthesis of combretastatin D-2 phosphate and dihydro-combretastatin D-2

George Pettit; Peter D. Quistorf; Jeremy A. Fry; Delbert L. Herald; Ernest Hamel; Jean Chapuis

doi:10.1021/np800635h

Antineoplastic agents. 565. Synthesis of combretastatin D-2 phosphate and dihydro-combretastatin D-2

George Pettit, Peter D. Quistorf, Jeremy A. Fry, Delbert L. Herald, Ernest Hamel, Jean Chapuis

Research output: Contribution to journal › Article › peer-review

18 Scopus citations

Abstract

A modified synthetic route to combretastatin D-2 (5) was devised in order to further evaluate its biological activity, for its conversion to phosphate prodrugs (25-28), and as a route to obtaining dihydro-combretastatin D-2 (42). A parallel first total synthesis of dihydro-combretastatin D-2 was completed, proceeding from a saturated 3-phenylpropionic ester intermediate via the Ullmann biaryl ether reaction (39-41). In contrast to the cancer cell growth inhibitory activity exhibited by combretastatin D-2, relatively minor structural modifications (41, 42) caused elimination of those properties.

Original language	English (US)
Pages (from-to)	876-883
Number of pages	8
Journal	Journal of Natural Products
Volume	72
Issue number	5
DOIs	https://doi.org/10.1021/np800635h
State	Published - May 22 2009

ASJC Scopus subject areas

Analytical Chemistry
Molecular Medicine
Pharmacology
Pharmaceutical Science
Drug Discovery
Complementary and alternative medicine
Organic Chemistry

Access to Document

10.1021/np800635h

Fingerprint Dive into the research topics of 'Antineoplastic agents. 565. Synthesis of combretastatin D-2 phosphate and dihydro-combretastatin D-2'. Together they form a unique fingerprint.

Cite this

@article{840d7ea2e16346e0aabe6d43425c56c8,

title = "Antineoplastic agents. 565. Synthesis of combretastatin D-2 phosphate and dihydro-combretastatin D-2",

abstract = "A modified synthetic route to combretastatin D-2 (5) was devised in order to further evaluate its biological activity, for its conversion to phosphate prodrugs (25-28), and as a route to obtaining dihydro-combretastatin D-2 (42). A parallel first total synthesis of dihydro-combretastatin D-2 was completed, proceeding from a saturated 3-phenylpropionic ester intermediate via the Ullmann biaryl ether reaction (39-41). In contrast to the cancer cell growth inhibitory activity exhibited by combretastatin D-2, relatively minor structural modifications (41, 42) caused elimination of those properties.",

author = "George Pettit and Quistorf, {Peter D.} and Fry, {Jeremy A.} and Herald, {Delbert L.} and Ernest Hamel and Jean Chapuis",

year = "2009",

month = may,

day = "22",

doi = "10.1021/np800635h",

language = "English (US)",

volume = "72",

pages = "876--883",

journal = "Journal of Natural Products",

issn = "0163-3864",

publisher = "American Chemical Society",

number = "5",

}

TY - JOUR

T1 - Antineoplastic agents. 565. Synthesis of combretastatin D-2 phosphate and dihydro-combretastatin D-2

AU - Pettit, George

AU - Quistorf, Peter D.

AU - Fry, Jeremy A.

AU - Herald, Delbert L.

AU - Hamel, Ernest

AU - Chapuis, Jean

PY - 2009/5/22

Y1 - 2009/5/22

N2 - A modified synthetic route to combretastatin D-2 (5) was devised in order to further evaluate its biological activity, for its conversion to phosphate prodrugs (25-28), and as a route to obtaining dihydro-combretastatin D-2 (42). A parallel first total synthesis of dihydro-combretastatin D-2 was completed, proceeding from a saturated 3-phenylpropionic ester intermediate via the Ullmann biaryl ether reaction (39-41). In contrast to the cancer cell growth inhibitory activity exhibited by combretastatin D-2, relatively minor structural modifications (41, 42) caused elimination of those properties.

AB - A modified synthetic route to combretastatin D-2 (5) was devised in order to further evaluate its biological activity, for its conversion to phosphate prodrugs (25-28), and as a route to obtaining dihydro-combretastatin D-2 (42). A parallel first total synthesis of dihydro-combretastatin D-2 was completed, proceeding from a saturated 3-phenylpropionic ester intermediate via the Ullmann biaryl ether reaction (39-41). In contrast to the cancer cell growth inhibitory activity exhibited by combretastatin D-2, relatively minor structural modifications (41, 42) caused elimination of those properties.

UR - http://www.scopus.com/inward/record.url?scp=66449124775&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=66449124775&partnerID=8YFLogxK

U2 - 10.1021/np800635h

DO - 10.1021/np800635h

M3 - Article

C2 - 20161135

AN - SCOPUS:66449124775

VL - 72

SP - 876

EP - 883

JO - Journal of Natural Products

JF - Journal of Natural Products

SN - 0163-3864

IS - 5

ER -